Cover Image
市場調查報告書

全球抗凝血劑市場

Anticoagulants

出版商 Global Industry Analysts, Inc. 商品編碼 138649
出版日期 內容資訊 英文 285 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球抗凝血劑市場 Anticoagulants
出版日期: 2018年02月01日 內容資訊: 英文 285 Pages
簡介

本報告提供全球抗凝血劑市場相關調查分析,提供各產品區隔,地區 (美國,加拿大,日本,歐洲,亞太地區,南美,其他) 別的市場實際成果與預測,主要企業簡介等系統性資訊。

第1章 簡介,調查手法,產品定義

第2章 摘要整理

  • 全球市場概要
    • VTE
    • 新的口服抗凝血劑推動市場
    • 市場規模
    • 安全性的問題
    • 抗凝血劑:從注射型到口服型
    • 傳統的口服藥
    • NOAC的新改良
    • 高齡化:重要促進因素
    • 心血管疾病的全球性威脅等
  • 市場趨勢與問題點
    • NOAC的崛起
    • NICE指南
    • 抗血小板治療的替代性NOAC
    • 肝素的交易增加促進市場
    • 現代的開發
    • NOAC和最新的健康風險間的相關關係等
  • 市場區隔分析
  • 治療的適應
  • 產品的介紹/核准
  • 近來產業活動
  • 全球主要企業
    • Abbott India Limited (印度)
    • Aspen Holdings (南非)
    • Bayer AG (德國)
    • Boehringer Ingelheim (德國)
    • Bristol-Myers Squibb Company (美國)
    • 田邊三菱製藥 (日本)
    • Pfizer, Inc. (美國)
    • Sanofi S.A. (法國)
    • Teva Pharmaceutical Industries Ltd. (以色列)
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

第4章 競爭情形

  • 企業簡介:48公司 (包含事業部/子公司的話是58公司)
    • 美國
    • 日本
    • 歐洲
    • 亞太地區 (日本以外)
    • 非洲

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1205

This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 48 companies including many key and niche players such as -

Abbott India Limited
Aspen Holdings
Bayer AG
Boehringer Ingelheim
Bristol-Myers Squibb Company
Mitsubishi Tanabe Pharma Corporation

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

  • Oral Anticoagulants
  • Injectable Anticoagulants

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

  • Venous ThromboEmbolism (VTE) - A Prelude
  • Anticoagulants Market Driven by Novel Oral Anti-coagulants
  • Sizing the Market
  • Safety Issues Associated with Erstwhile Market Leaders - Warfarin & Heparins
  • Anticoagulants - Evolution from Injectables to Oral Drugs
  • Conventional Oral Drug - Warfarin - Face the Heat
  • The Newer Breed of NOACs
  • Comparative Analysis of Warfarin and Novel Oral Anticoagulants
    • Table 1: Global Market for Leading Oral Drugs (2016): Percentage Market Share Breakdown of Value Sales for Eliquis, Xarelto, Pradaxa, and Others (includes corresponding Graph/Chart)
  • Bevyxxa (Betrixaban) - The Latest Approved NOAC
  • Aging Population: A Crucial Driver for Anticoagulants Market
    • Table 2: Global Population Statistics for the 60+ Age Group by Region (2017) (includes corresponding Graph/Chart)
    • Table 3: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    • Table 4: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 5: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)
    • Table 6: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
  • Global Menace of Cardiovascular Disease - A Major Growth Factor
    • Table 7: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
    • Table 8: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
  • Increasing Prevalence of AF Impacts Growth Prospects
  • Rising Stroke Statistics - An Opportunity Indicator for Anticoagulants
  • Increasing Incidence of Knee/Hip Replacement Surgeries Drive Market Growth
    • Table 9: Hip Replacement per 100,000 Population in Select Countries (includes corresponding Graph/Chart)
    • Table 10: Knee Replacement per 100,000 Population in Select Countries (includes corresponding Graph/Chart)
  • Increasing Healthcare Spending in Emerging Markets
    • Table 11: Healthcare Spending as a Percentage of GDP by Region: 2016 (includes corresponding Graph/Chart)
    • Table 12: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2016) (includes corresponding Graph/Chart)
  • Adverse Effects: A Key Market Deterrent
  • Common Adverse Effects of NOAC Therapies
  • Increased Bleeding - A Major Concern with Newer Agents
  • Novel Oral Drugs: Absence of Antidote & Other Concerns
  • US FDA Delays Andexxa (the Xarelto and Eliquis Antidote) Approval
  • Reversal Agents for DOACs
  • Threat of Generics Looms Large on the Anti-Coagulants Market
  • Patent Expiries of Oral Anticoagulants
  • Pipeline Analysis
  • Tecarfarin (Espero BioPharma)
  • List of Ongoing NOAC Studies

2. MARKET TRENDS & ISSUES

  • NOACs to Emerge as Mainstream Option for VTE Patients
  • NICE Guidelines Promote NOAC Usage in Atrial Fibrillation
  • NOACs as Alternative/Supplement to Antiplatelet Therapy
  • Increase in Heparin Trade Boosts the Market
  • Modern Developments Improving Anticoagulation Management
  • Researchers Find Significant Correlation between NAOC and Newer Health Risks
  • NOAC Underdosing Trend Restrains Universal Acceptance
  • Underutilization of Oral Anticoagulants in Atrial Fibrillation
  • Generics Prevail in the Traditional Market
  • Patent Expiries of Traditional Anticoagulants in the US
  • Inadequate Trials Mar Pediatric Anticoagulants Market
  • New Advancements Improve Anticoagulation Management
  • Growing Demand for Self-Testing
  • LMWHs Ease Outpatient Management

3. SEGMENT ANALYSIS

  • Oral Anticoagulant Agents
  • Traditional Oral Anticoagulants
  • Warfarin
    • Coumadin - The Branded Warfarin
    • Advantages and Alternatives
    • Side Effects
    • Limitations
  • Novel Oral AntiCoagulants (NOAC)
  • Approved Indications of Various NOACs by Geographic Region
  • Approved Anticoagulant Agents in a Nutshell
  • Pradaxa (Dabigatran Etexilate)
    • Pradaxa and Warfarin - A Comparative Study
  • Xarelto (Rivaroxaban)
    • Xarelto Patent Expiry in Various Regions
  • Apixaban (Eliquis)
  • Savaysa (Edoxaban)
  • Bevyxxa (betrixaban)
  • Injectable Anticoagulants
  • Injectable Anticoagulants - An Insight
  • Heparin - The Backbone of Injectable Anticoagulants
    • Unfractionated Heparin
      • Advantages and Alternatives
      • Limitations
    • Low Molecular Weight Heparins (LMWH)
      • Indications
      • Advantages
    • A Focus on Select Heparin-based Injectables
      • Lovenox/Clexane (enoxaparin)
      • Approved Indications for Lovenox
      • Advantages and Alternatives
      • Fragmin (dalteparin sodium)
      • Approved Indications for Fragmin Use
      • Fraxiparine (nadroparin)
      • Innohep (tinzaparin)
      • Normiflo (ardeparin)
      • Clivarine (reviparin)
    • Non-Heparin Anticoagulant Injectables - An Overview
      • Arixtra (fondaparinux)
      • Angiomax (bivalirudin)
      • Advantages
      • Argatroban/Novastan
      • Side Effects

4. THERAPEUTIC INDICATIONS

  • Venous/DVT Thrombosis Indications
  • Venous Thromboembolism
  • Venous Thromboembolism-Causes and Symptoms
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Orthopedic (Hip or Knee Replacement) Surgery
  • General Surgery
  • Cancer
  • Arterial Thrombosis Indications
  • Arterial Thrombosis
  • Acute Coronary Syndromes
  • Atrial Fibrillation
  • Unstable Angina
    • List of Approved Anticoagulants for Unstable Angina
  • Myocardial Infarction
  • Non ST-Segment Elevation MI
  • Percutaneous Transluminal Coronary Angioplasty (PTCA)
  • Heparin Induced Thrombocytopenia (HIT) Indications
  • Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
  • Other Indications
  • Hemodialysis

5. PRODUCT INTRODUCTIONS/APPROVALS

  • Mylan Pharmaceuticals Inc. Agrees to hold off Pradaxa's generic version
  • Portola Pharmaceuticals Declares Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
  • Daiichi Sankyo Introduces Anticoagulant Lixiana OD Tablets
  • FDA again Delays Approval of AndexXa
  • US FDA Approves Bayer's Xarelto
  • Portola Pharmaceuticals Receives U.S FDA Approval for Bevyxxa
  • Armetheon Receives European Medicines Agency's Support for Studying Tecarfarin prior to MAA Filing
  • Armetheon Agrees with FDA for Conducting a Study for Tecarfarin Prior to NDA Filing
  • Rivaroxaban (Xarelto) Receives Patent Term Extension in US
  • Armetheon Declares Positive Results of Tecarfarin versus Warfarin
  • FDA Approves Pradaxa Antidote Praxbind
  • CFDA Approves Bayer's Xarelto
  • Raplixa Anticoagulant by MDCO Receives FDA Approval
  • Teva Launches Argatroban Injection in the US Market
  • BMS and Pfizer Announce Phase III Results of Apixaban
  • Boehringer Ingelheim Receives Priority Review by FDA for Idarucizumab BLA
  • FDA Grants Fast Track Designation to Perosphere's PER977
  • FDA Approves Savaysa/Edoxaban

6. RECENT INDUSTRY ACTIVITY

  • Daiichi Sankyo Introduces Anticoagulant Lixiana(r) OD Tablets in Japan
  • Bristol-Myers Squibb and Pfizer Presents New Analyses for Eliquis(tm) (apixaban) Clinical and Real-World Data
  • Espero Pharmaceuticals and Armetheon Plans to Merge
  • Portola Pharmaceuticals Signs a Loan Agreement with Pfizer and Bristol-Myers Squibb
  • Momenta Pharmaceuticals Presents Data on Necuparanib at the ASCO Annual Meeting
  • Reig Jofre Acquires Chiesi Espana SA a sodium heparin
  • Chiesi Acquires Three Hospital Products -- Kengreal(r), Cleviprex(r) and Argatroban(tm) for Injection
  • Bayer Collaborates with Janssen on Extended Clinical Investigation of Xarelto
  • Bayer to Acquire Experimental Anticoagulant from Isis Pharmaceuticals

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott India Limited (India)
  • Aspen Holdings (South Africa)
  • Bayer AG (Germany)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Pfizer, Inc. (USA)
  • Sanofi S.A. (France)
  • Teva Pharmaceutical Industries Ltd. (Israel)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 15: World 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Oral Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 18: World 14-Year Perspective for Oral Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Injectable Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 21: World 14-Year Perspective for Injectable Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 22: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 23: World Historic Review for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 24: World 14-Year Perspective for Injectable Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 25: World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Unfractionated Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 27: World 14-Year Perspective for Unfractionated Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 28: World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 29: World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 30: World 14-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Key Statistics
    • US: The Largest Market for Anti-Coagulants
      • A List of FDA Approved Anticoagulants
    • Eliquis and Xarelto lead the US NOAC Market
    • Table 31: The US Oral Anti-Coagulants Market by Leading Players (2016): Market Share of Breakdown of Total Prescriptions for Warfarin, Xarelto, Eliquis, Pradaxa, and Savaysa (includes corresponding Graph/Chart)
    • Table 32: The US Oral Anti-Coagulants Market by Leading Players (2016): Market Share of Breakdown of Total Sales for Xarelto, Eliquis, Pradaxa, and Others (includes corresponding Graph/Chart)
    • AndexXa - Another Reversal Agent for NOAC
    • Growth Drivers/Trends
      • Atrial Fibrillation - A Key Risk Factor, Driving the Demand for Anti-Coagulants
      • Rapidly Ageing Demographics Drive Growth in the Anticoagulants Market
    • Table 33: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Surge in CVD Incidence - Major Growth Factor
    • Table 34: CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)
    • Table 35: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)
    • Manufacturers' Patient Assistance Programs Support Increased Sales
    • US Injectable Anti-Coagulants Market
    • Decline in Heparin Demand
    • Extending the Use of Heparin to New Indications
    • Product Introductions/Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 36: The US Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 37: The US Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 38: The US 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 39: Canadian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 40: Canadian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 41: Canadian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population Spurs Growth of Anticoagulants
    • Table 42: Japanese Aging Population by Age Group: Year Ending June 1, 2017 (includes corresponding Graph/Chart)
    • Product Launches
    • Select Key Players
  • B. Market Analytics
    • Table 43: Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 44: Japanese Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 45: Japanese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Europe: A Major Anti-Coagulant Market
    • Increasing Aging Population Boosts Demand
    • Table 46: Aged Population in the EU (2016): Population Over 65+ Years as % of Total Population (includes corresponding Graph/Chart)
    • New Drugs Drive Use of Oral Anticoagulants in Atrial Fibrillation Patients
  • B. Market Analytics
    • Table 47: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 48: European Historic Review for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 49: European 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 50: European Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 51: European Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 52: European 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Sanofi S.A. - A Key Player
  • B. Market Analytics
    • Table 53: French Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 54: French Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 55: French 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Strategic Corporate Developments
    • Focus on Select Key Players
  • B. Market Analytics
    • Table 56: German Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 57: German Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 58: German 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 59: Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 60: Italian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 61: Italian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Stroke Statistics - Opportunity Indicator for Anticoagulants
    • NICE Guidelines Promote NOAC Usage
  • B. Market Analytics
    • Table 62: The UK Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 63: The UK Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 64: The UK 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 65: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 66: Spanish Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 67: Spanish 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 68: Russian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 69: Russian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 70: Russian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 71: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 72: Rest of Europe Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 73: Rest of Europe 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Highly Populated Asian Countries Offer Significant Growth Opportunities
    • Table 74: Over 65 Years Individuals as % of the Total Population in Select Asian Countries: 2016 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 75: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 76: Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 77: Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 78: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 79: Asia-Pacific Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 80: Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Favorable Reimbursement for NOACs
    • LMWH - The leading Heparin Segment
    • Product Launch
  • B. Market Analytics
    • Table 81: Chinese Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 82: Chinese Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 83: Chinese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • Abbott India Limited - A Key Player
  • B. Market Analytics
    • Table 84: Indian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 85: Indian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 86: Indian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • Market Analysis
    • Table 87: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 88: Rest of Asia-Pacific Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 89: Rest of Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 90: Latin American Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 91: Latin American Historic Review for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 92: Latin American 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 93: Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 94: Latin American Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 95: Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6a. BRAZIL

  • Market Analysis
    • Table 96: Brazilian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 97: Brazilian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 98: Brazilian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6b. REST OF LATIN AMERICA

  • Market Analysis
    • Table 99: Rest of Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 100: Rest of Latin American Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 101: Rest of Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Select Key Players
  • B. Market Analytics
    • Table 102: Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 103: Rest of World Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 104: Rest of World 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Back to Top